Testing remains cash cow for medical device companies To view this email as a web page,
click here Johnson & Johnson sees 'very viable path forward' for its COVID-19 vaccine despite safety, manufacturing setbacks Abbott, J&J post rebounds in surgical sales, while COVID testing remains a cash cow for now Bharat Biotech, government cash and partners in hand, aims for 700M COVID-19 shots per year Global investment in telehealth, artificial intelligence hits a new high in Q1 2021 UPDATED Coronavirus tracker: Amazon's Alexa now able to connect users to vaccine sites PPD-backed siteless trial specialist Medable reels in $78M as the pandemic continues to push its biz forward COVID-19 tracker: J&J resumes vaccine rollout in Europe; AstraZeneca's delayed COVAX supply resolved: UNICEF Featured Story | By Eric Sagonowsky Johnson & Johnson's COVID-19 vaccine launch has hit pitfall after pitfall, but execs say they're confident the company can get back up to speed. The drugmaker plans to work with the FDA on a manufacturing site inspection and is 'cautiously optimistic' regulators will see the shot's benefits outweigh its risks. read more |
| |
|---|
|
Top Stories By Conor Hale Medical device companies continue to see their surgical sales recover to pre-COVID levels, and they're now delivering the first quarterly results that compare earnings to the earliest stages of the pandemic. read more By Fraiser Kansteiner India's Bharat Biotech is gunning to produce 700 million doses of its COVID-19 shot Covaxin a year, and it's won government cash and three new manufacturing partners help it reach that goal. read more By Heather Landi The first quarter of 2021 continued to see strong investor interest following 2020’s record highs. Telehealth investment hit an all-time high of $4.2 billion in just 139 deals in the first quarter of 2021. Healthcare AI also broke another funding record, according to CB Insights. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams Decentralized study company Medable has raised $78 million in its third funding round less than six months after grabbing $91 million. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky Johnson & Johnson said it will resume its European vaccine rollout after the European Medicines Agency said the shot’s benefits still outweigh its risks, Reuters reports. Supply issues that hindered deliveries of AstraZeneca's vaccine to COVAX have been resolved, a UNICEF representative says. And more headlines. read more |
|
